• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Infect Dis . Serologic Testing for Middle East Respiratory Syndrome Coronavirus and SARS-CoV-2 Cross-Reactive Immune Responses, the Netherlands

tetano

Editor, Senior Moderator
Emerg Infect Dis

. 2026 Nov;32(11):1874-1878.
doi: 10.3201/eid3211.260690.

Serologic Testing for Middle East Respiratory Syndrome Coronavirus and SARS-CoV-2 Cross-Reactive Immune Responses, the Netherlands​


Merel R Te Marvelde, Anna Z Mykytyn, Matthijs P Raadsen, Alexandre H J Bouffier, Sivana Baptista Varela, Rory D de Vries, Corine H GeurtsvanKessel, Bart L Haagmans



Free article

Abstract​


Cross-reactive SARS-CoV-2-specific antibodies could compromise the specificity of MERS-CoV serology, potentially leading to misclassification of infection history. SARS-CoV-2 exposure induced MERS-CoV antibodies primarily targeting the conserved S2 domain, with occasional neutralizing capacity. Combining MERS-CoV S1 binding with neutralization, however, limited the influence of SARS-CoV-2-induced cross-reactivity on MERS-CoV serology.

Keywords: COVID-19; MERS; MERS-CoV; Middle East respiratory syndrome coronavirus; SARS-CoV-2; cross-reactivity; diagnostics; respiratory infections; serology; severe acute respiratory syndrome coronavirus 2; the Netherlands; vaccination; viruses.
 
Back
Top Bottom